Top Markets
#1 Official Trump Official Trump +51.60%
#2 Mubarak Mubarak +28.48%
#3 Melania Meme Melania Meme +26.88%
#4 Movement Movement +26.70%
#5 Zama Zama +26.06%
#6 EXOD EXOD +22.08%
#7 Pearl Pearl +21.29%
#8 Wrapped POL Wrapped POL +18.85%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.51%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.86%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rank in Stocks #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.7426
Last synced: 2026-08-21
Market Cap
$69.05M
Change (1 day)
-2.17%
Change (1 year)
-57.57%
Country
US
Trade Citius Oncology, Inc. (CTOR)

Category

Healthcare
P/E ratio for Citius Oncology, Inc. (CTOR)
P/E ratio as of 2026 TTM: 0
According to Citius Oncology, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Citius Oncology, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.